Skip to content
Blackberry Empire – Lifestyle
Author:
Io Therapeutics, Inc.
RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models
August 5, 2026
Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
March 25, 2026
Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention
March 11, 2026